SURAKSHA326.20

Suraksha Diagnostic Limited

· Pharma & Health
AnnualQuarterly₹ CrorePeersKRSNAAHEALTHXNEPHROPLUS3BBLACKBIOMcap ₹1,699 Cr
View
In ₹ Crore except Per Share
12 Months Ending
Q2 FY25
30/09/2024
Q3 FY25
31/12/2024
Q4 FY25
31/03/2025
Q1 FY26
30/06/2025
Q2 FY26
30/09/2025
Q3 FY26
31/12/2025
Q4 FY26
31/03/2026
Q1 FY27
30/06/2026
Revenue from Operations66.859.565.172.678.775.681.487.6
Other Income1.30.60.80.90.91.00.81.1
Total Income68.160.165.973.579.676.682.288.7
Expenses
+ Cost of Materials Consumed7.96.18.88.88.98.610.210.0
+ Employee Benefit Expense11.011.310.212.813.413.013.714.4
+ Finance Costs2.12.02.12.72.83.13.93.7
+ Depreciation & Amortisation8.78.88.79.510.110.111.311.3
+ Other Expenses24.623.926.927.332.330.833.232.8
Total Expenses54.452.156.761.067.565.672.272.2
EBITDA23.218.319.223.824.123.224.430.4
EBIT14.49.410.514.314.013.113.119.2
Profit
PBT before Exceptional Items13.68.09.212.512.011.010.016.5
Pretax Income13.68.09.212.512.011.010.016.5
+ Current Tax3.62.21.52.93.12.42.44.2
+ Deferred Tax-0.1-0.10.60.40.10.41.4-0.6
Tax Expense3.52.12.03.33.22.83.83.7
Net Income10.26.07.29.28.88.16.212.8
+ Net Income — Continuing Ops10.26.07.29.28.88.16.212.8
+ Other Comprehensive Income0.00.1-0.10.2-0.00.10.30.1
Total Comprehensive Income10.26.17.19.48.88.26.413.0
Net Income to Common10.37.49.49.00.06.313.0
Minority Interest-0.2-0.2-0.2-0.20.0-0.1-0.2
Per Share
Basic EPS1.941.181.421.801.731.561.212.50
Diluted EPS1.941.181.421.801.731.561.212.50
Other Comprehensive Income — detail
+ Other Comprehensive Income-0.10.2-0.00.10.30.1
+ Items NOT to be Reclassified to P&L0.00.1-0.10.2-0.00.10.30.1
Comprehensive Income — Owners of Parent10.46.27.39.69.00.06.613.2
Comprehensive Income — Non-controlling Interests-0.2-0.2-0.2-0.2-0.20.0-0.1-0.2
Per Share — as-filed variants
Basic EPS — Continuing Operations1.941.181.421.801.731.561.212.50
Diluted EPS — Continuing Operations1.941.181.421.801.731.561.212.50
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit58.853.456.263.869.867.071.377.7
Gross Margin %88.1289.7486.4187.9488.6988.6587.5288.60
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)13.68.09.212.512.011.010.016.5
Net Income Adj (tax-effected)10.26.07.29.28.88.16.212.8
EPS Adj1.941.181.421.801.731.561.212.50
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value2.002.002.002.002.002.002.002.00
Paid Up Equity Capital8.610.410.410.410.410.410.410.4
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.